Karen Gheesling Mullis

Dr. Karen Gheesling Mullis has 30 plus years of experience in academic and pharmaceutical R&D and serves as Director of New Ventures, in the Washington University in St. Louis Office of Technology Management.  She worked in the biotech startup space first as a Venture Partner, President of Archer Seed Fund with RiverVest Venture Partners, and then in operational roles at Wugen, a RiverVest founded company, helping grow the company from employee #1 to a clinical stage biotech.  She spent over 20 years with Pfizer and heritage Pharmacia/Searle, where she was asset project manager and operations team leader in Oncology Clinical Development leading teams from IND to product launch including  IBRANCE™.  Dr. Gheesling Mullis received her BS in Chemistry from Emory University, her PhD in Biochemistry from University of Alabama in Birmingham.  She first came to Washington University for her post-doctoral training with Dr.  Rosalind Kornfeld, Professor of Biochemistry at the School of Medicine.